Business
In a hot stock market, biotechnology is running a fever.
Oct. 23, 1991
Centocor Inc., one of the few biotechnology companies with products and profits, ended talks with Johnson & Johnson about buying Centocor, a person familiar with the situation said.
May 13, 1999
Centocor Tumbles on FDA Setback: Centocor Inc., a highflying biotechnology stock just months ago, came crashing down after the company announced that the Food and Drug Administration had rejected its test results for a genetically engineered drug called Centoxin, which is designed to treat potentially fatal bacterial infections.
April 16, 1992
Centocor Inc. stopped testing its flagship drug in the United States and suspended sales in Europe on Monday, saying increasing numbers of people have died after receiving the treatment.
Jan. 19, 1993
Science & Medicine
Medicine: Anti-clotting agent modeled after snake venom could avert 10,000 deaths a year, researchers say.
March 18, 1997
Lilly Buys Marketing Rights to Drug: In the latest in a series of deals to market products developed by other companies, Eli Lilly & Co. said it was investing at least $100 million in Centocor Inc.
July 17, 1992
Centocor to End U.S.
March 16, 1993
World & Nation
Health: Johnson & Johnson-Centocor deal comes as pharmaceutical firms seek growth areas.
July 22, 1999
Wellcome Cleared to Market Centocor’s Cancer Drug: The British drug maker has been given the green light to market a treatment for postoperative colorectal cancer patients, developed in Germany by Centocor.
Jan. 5, 1995
Centocor Stock Gains 68% After Tests: Shares of the biotechnology company surged after it reported early positive test results that could significantly expand the use of its blood clot-busting drug ReoPro.
Dec. 16, 1995